Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
COPD
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
Do findings from the
STARR2
trial influence your approach?
Related Questions
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
Are the results of the BOREAS trial generalizable to non-white populations?
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
Have you implemented the Rome proposal for COPD exacerbations?
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?